MONMOUTH JUNCTION, N.J.,
June 1, 2021 /PRNewswire/ -- CytoSorbents
Corporation (NASDAQ: CTSO), a critical care therapy leader
commercializing its CytoSorb® blood purification technology to
treat deadly conditions in critically ill and cardiac surgery
patients around the world, announces the appointment of
Terri Anne Powers, MBA, IRC, as Vice
President of Investor Relations and Corporate Communications
effective today.
CytoSorbents hires Terri Anne Powers
as VP of IR and Corporate Communications to build best-in-class
investor relations
Ms. Powers was most recently Vice President of Investor
Relations at publicly-traded Diplomat Pharmacy, Inc., the largest
independent provider of specialty pharmacy services in the United States, prior to its acquisition in
2020. At Diplomat, she established the in-house investor
relations function and supported overall corporate
communications. Prior to Diplomat, Ms. Powers spent nine
years as Director of North American Investor Relations for
France-based Veolia Environnement,
a publicly-traded global water, waste, and energy services
leader.
Powers has more than 15 years of experience in the healthcare
industry. In addition to her time at Diplomat, Powers spent
seven years as an associate sell side analyst covering healthcare
distribution and services equities at Robert W. Baird and
Prudential Securities. Ms. Powers started her career as a
chemist conducting research and development in the pharmaceutical
industry at the G.D. Searle unit of Monsanto, where she also held
other roles in preclinical drug development and as a global market
research analyst.
Ms. Powers received her M.B.A. in finance and strategic
management from the University of
Chicago Booth School of Business. She received her
B.S. in chemistry from Alma College,
where she graduated with summa cum laude and Phi Beta Kappa
honors. Ms. Powers is also an active member of NIRI, the
National Investor Relations Institute, and holds the Investor
Relations Charter (IRC) credential.
Ms. Powers stated, "I am thrilled to join CytoSorbents at such
an exciting time and look forward to working with the leadership
team and Board of Directors to increase the Company's visibility in
the capital markets and broader stakeholder community. A key
focus will be to foster an open dialog with all current and
prospective investors, while systematically cultivating and
expanding the shareholder base to a broader set of investors, both
domestic and international. I believe that CytoSorbents'
mission to save lives through blood purification is such a
compelling story that it needs to be heard more broadly."
Dr. Phillip Chan, Chief Executive
Officer of CytoSorbents stated, "We are delighted to welcome
Terri Anne as Vice President of
Investor Relations and Corporate Communications, bringing this
position in-house for the first time. Terri Anne has established a reputation in the
healthcare industry as a smart, credible, articulate, and
responsive IR professional and analyst, with strong relationships
among many major investors. The dedicated focus and skill set
she brings to CytoSorbents is perfectly timed as we communicate our
exciting growth story and path to potential U.S. FDA approval to
investors, our business partners, and the medical community
worldwide."
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 68 countries around the world, as an extracorporeal
cytokine adsorber designed to reduce the "cytokine storm" or
"cytokine release syndrome" that may result in massive
inflammation, organ failure and death in common critical illnesses.
These are conditions where the risk of death can be extremely high,
yet no effective treatments exist. CytoSorb® is also
being used during and after cardiac surgery to remove inflammatory
mediators that can lead to post-operative complications, including
multiple organ failure. CytoSorb® has been used in more than
131,000 human treatments to date. CytoSorb has received
CE-Mark label expansions for the removal of bilirubin (liver
disease), myoglobin (trauma), and both ticagrelor and
rivaroxaban during cardiothoracic surgery. CytoSorb has
also received FDA Emergency Use Authorization in the United States for use in critically ill
COVID-19 patients with imminent or confirmed respiratory failure,
in defined circumstances. CytoSorb has also been granted FDA
Breakthrough Designation for the removal of ticagrelor in a
cardiopulmonary bypass circuit during emergent and urgent
cardiothoracic surgery.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The Company has
numerous products under development based upon this unique blood
purification technology protected by many issued U.S. and
international patents and multiple applications pending, including
ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™,
VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and
others. For more information, please visit the
Company's websites at www.cytosorbents.com and
www.cytosorb.com or follow us on Facebook and
Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2021, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
CytoSorbents Investor Relations Contact:
Terri Anne Powers
Vice President of Investor Relations and Corporate
Communications
732-482-9984
tpowers@cytosorbents.com
Public Relations Contact:
Eric
Kim
Rubenstein Public Relations
212-805-3055
ekim@rubensteinpr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytosorbents-appoints-terri-anne-powers-irc-as-vice-president-of-investor-relations-and-corporate-communications-301302741.html
SOURCE CytoSorbents Corporation